Sarepta Therapeutics surges 32% on expanded FDA approval for Duchenne gene therapy By Investing.com
Investing.com - Sarepta Therapeutics (NASDAQ:), a pioneer in precision genetic drugs for uncommon illnesses, surged in Thursday's after-hours offers after ...
